Membrane disrupting lytic peptides for cancer treatments

Current Pharmaceutical Design

Volumn 10, Issue 19, 2004, Pages 2299-2310

  Leuschner, Carola ^a   Hansel, William ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Antitumoral drugs; Cancer treatment; Cell selectivity; Conjugated lytic peptides; Lytic peptide

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CECROPIN A; CECROPIN B; CECROPIN B 1; CECROPIN B 2; CECROPIN B 3; CHORIONIC GONADOTROPIN; D2A21 PROTEIN; HECATE; LACTOFERRIN; LACTOFERRIN 5; LUTEINIZING HORMONE; MAGAININ; MAGAININ 2; MAGAININ A; MAGAININ B; MAGAININ G; MELITTIN; MSI 130; MSI 136; MSI 238; MSI 511; OLP 1 PROTEIN; PEPTIDE DERIVATIVE; PHOR 14; PHOR 21; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALPHA HELIX; ANTIGENICITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BACTERIAL CELL; CANCER; CANCER CHEMOTHERAPY; CELL DESTRUCTION; CELL SELECTION; CONJUGATION; CYTOLYSIS; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG RESEARCH; DRUG SENSITIVITY; DRUG STRUCTURE; ERYTHROCYTE; HOST RESISTANCE; HUMAN; INSECT; INVERTEBRATE; MAMMAL CELL; MEMBRANE DAMAGE; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; TUMOR CELL; VERTEBRATE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL MEMBRANE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PEPTIDES; PROTEIN CONFORMATION;

EID: 3042737827     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383971     Document Type: Review

References (81)

1. Fitton JE, Dell A, Shaw WV. The amino acid sequence of the delta haemolysin of Staphylococcus aureus. FEBS Lett 1980; 115: 209-12.
2. Haberman E, Jentsch J. Sequenzanalyse des melittins aus den tryptischen und peptischen Spaltstuecken. Hoppe Seylers Z Physiol Chem 1967; 348: 37-50.
3. Boman HG, Hultmark D. Cell free immunity in insects. Ann Rev Microbiol 1987; 41: 103-126.
4. Steiner H, Hultmark D, Engstrom A, Bennich H, Boman HG. Sequence and specificity of trwo antibacterial proteins involved in insect immunity. Nature 1981; 292:246-8.
5. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 1987; 84: 5449-5453.
6. Selstedt ME, Brown DM, DeLange RJ, Lehrer RI. Primary structures of MCP-1 and MCP-2, natural peptide antibiotics of rabbit lung macrophages. J Biol Chem 1983; 258: 14485-9.
7. Lee JY, Boman A, Sun CX, Andersson M, Jornvall H, Mutt V, et al. Antibacterial peptides from pig intestine: isolation of a mammalian cecropin. Proc Natl Acad Sci USA 1989; 86: 9159-9162.
8. Ganz T, Selstedt ME, Szklarek D, Harwig SS, Daher K, Bainton DF, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985; 76: 1427-1435.
9. Chen HM, Wang W, Smith DK, Chan SC. Effects of the antibacterial peptide cecropin B and its analogs, cecropin B-1 and B-2, on liposomes, bacteria and cancer cells. Biochim Biophys Acta 1997; 1336: 171-179.
10. Mor A, Nguyen VH, Delfour A, Migliore-Samour D, Nicolas P. Isolation, amino acid sequence, and synthesis of dermaseptin, a novel antimicrobial peptide of amphibian skin. Biochemistry 1991; 30: 8824-8830.
11. Shai Y, Fox J, Caratsch C, Shih YL, Edwards C, Lazarovici P. Sequencing and synthesis of pardaxin, a polypeptide from the Red Sea Moses sole with ionophore activity. FEBS Lett 1988; 242: 161-168.
12. Leippe M, Tannich E, Nickel R, Van der Goot G, Pattus F, Horstmann RD, Mueller Eberhard HJ. Primary and secondary structure of the pore-forming peptide of the pathogenic Entamoeba histolytica. EMBO J 1992; 11: 3501-3506.
13. Gennaro R, Zanetti M, Benincasa M, Podda E, Miani M. Pro-rich antimicrobial pepetides from animals: Structure, biological functions and mechanism of action. Curr Pharm Design 2002; 8: 763-778.
14. Ehret-Sabatier L, Loew D, Goyffon M, Fehlbaum P, Hoffmann JA, von Dorsselaer A, et al. Characterization of novel cytstine-rich antimicrobial peptides from scorpion blood. J Biol Chem 1996; 271: 29537-29544.
15. Hetru C, Letellier L, Oren Z, Hoffmann JA, Shai Y. Androctonin, a hydrophilic disulphide-bridged non haemolytic anti-microbial peptide, a plausible mode of action. Biochem J 2000; 345: 656-664
16. Lambert J, Keppi E, Dimarcq JL, Wicker C, Teighart JM, Dunbar P. Insect immunity: isolation from immune blood of the dipteran Phormia terranovae of two insect antibacterial peptides with sequence homology to rabbit lung macrophage bactericidal peptides. Proc Natl Acad Sci USA 1989; 86: 262-266.
17. Hetru C, Hoffmann D, Bulet P. In: Brey PT, Hultmark D Eds, Molecular mechanisms of immune responses in insects. London, Chapman and Hall 1998; 40-66.
18. Boman HG. Antibacterial peptides: key components needed in immunity. Cell 1991; 65: 205-207.
19. Lehrer RI, Ganz T. Antimicrobial peptides in mammalian and insect host defense. Curr Opin Immunol 1999; 11: 23-27.
20. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenic perspectives in innate immunity. Science 1999; 284: 1313-1318.
21. Shai Y, Oren Z. Diastereoisomers of cytolysins, a novel class of potent antibacterial peptides. J Biol Chem 1996; 271: 7305-7308.
22. Oren Z, Shai Y. Selective lysis of bacteria but not mammalian cells by diastereomers of melittin: structure function study. Biochem 1997; 36: 1826-35.
23. Oren Z, Hong J, Shai J. A repertoire of novel antibacterial diastereomeric peptides with selective cytolytic activity. J Biol Chem 1997; 272: 14643-14649.
24. Dempsey CE. The actions of melittin on membranes. Biochim Biophys Acta 1990; 1031: 143-161.
25. Unger T, Oren Z, Shai Y. The effect of cyclization of magainin 2 and melittin analogues on structure, function and model membrane interactions: Implications to their mode of action. Biochemistry 2001; 40: 6388-6397.
26. Chen HM, Leung KW, Thakur NN, Tan A, Jack RW. Distinguishing between different pathways of bilayer disruption by the related antimicrobial peptides cecropin B, B1 and B3. Eur J Biochem 2003; 270: 911-920.
27. Chen HM, Clayton A, Wang W, Sawyer WH. Kinetics of membrane lysis by custom lytic peptides and peptide orientation in membrane. Eur J Biochem 2001; 268: 1659-1669.
28. Bechinger B. The structure, dynamics and orientation of antimicribial peptides in membranes by multidimensional solid-state NMR spectroscopy. Biochim Biophys Acta 1999; 1462: 157-183.
29. Sui SF, Wu H, Guo Y, Chen KS. Conformational changes of melittin upon insertion into phospholipid monolayer and vesicles. J Biochem 1994; 116: 482-487.
30. Ludtke SJ, He K, Wu Y, Huang HW. Cooperative membrane insertion of magainin correlated with its cytolytic activity. Biochim Biophys Acta 1994; 1190: 181-184.
31. Huang HW. Action of antimicrobial peptides: two state model. Biochemistry 2000; 39:8347-802.
32. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipids bilayer membranes by α-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1999; 1462: 55-70.
33. Silvestro L, Gupta K, Weiser JN, Axelson PH. The concetration dependent membrane activity of cecropin A. Biochemistry 1997; 36: 11452-11460.
34. Steiner H, Andreu D, Merrifield RB. Binding and action of cecropin and cecropin analogues: antibacterial peptides from insects. Biochim Biophys Acta 1988; 939: 260-266.
35. Andreu D, Rivas L. Animal antimicrobial peptides. Biopolymers 1999; 47: 415-433.
36. Resnick NM, Maloy WL, Guy HR, Zasloff M. A novel endopeptidase from Xenopus that recognizes alpha-helical secondary structure. Cell 1991; 66; 541-554.
37. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 1991; 51: 3062-3066.
38. Rothman JE, Lenard J. Membrane asymmetry. Science 195: 743-753.
39. Op dem Kamp JAF. Lipid asymmetry in membranes. Ann Rev Biochem 1979; 48: 47-71.
40. Chiu D, Lubin B, Shoehet SB. Erythrocyte membrane lipid reorganization during the sickling process. Br J Haematol 1979; 41: 223-234.
41. Papo N, Shahar M, Eisenbach L, Shai Y. A novel lytic peptide composed of DL amino acids selectively kills cancer cells in culture and in mice. J Biol Chem 2003; 278: 21018-21023.
42. Blondelle SE, Houghten RA. Design of model amphipathic peptides having potent antimicrobial activities. Biochemistry 1992; 31: 12688-12694.
43. Blondelle SE, Houghton RA. Probing the relationships between the structure and hemolytic activity of melittin with a complete set of leucine substitution analogs. Pept Res 1991; 4: 12-18.
44. Chen HC, Brown JH, Morell JL, Huang CM. Synthetic magainin analogues with improved antimicrobial activity. FEBS Lett 1988; 236: 462-466.
45. Kiyota T, Lee S, Sugihara G. Design and synthesis of amphiphilic -helical model peptides with systematically varied hydrophobic-hydrophilic balance and their interaction with lipid- and biomembranes. Biochemistry 1996; 35: 13196-13204.
46. Hong J, Oren Z, Shai Y. Structure and organization of hemolytic and nonhemolytic diastereomers of antimicrobial peptides in membranes. Biochemistry 1999; 38: 16963-16937.
47. Baker MA, Maloy WL, Zasloff M, Jacob LS. Anticancer efficacy of magainin 2 and analog peptides. Cancer Res 1993; 53: 3052-3057.
48. Javadpour MM, Juban MM, Lo WCJ, Bishop SM, Alberty B, Cowell, SM, Becker CL, McLaughlin ML. De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem 1996; 39: 3107-3113.
49. Cruciani RA, Barker JL, Zasloff M, Chen HC. Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. Poc Natl Acad Sci USA 1991; 88: 3792-3796.
50. Ohsaki Y, Gasdar AF, Chen HC, Johnson BE. Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res 1992; 52: 3534-3538.
51. Soballe PW, Maloy WL, Myrga ML, Jacob LS, Herlyn M. Experimental local therapy of human melanoma with lytic magainin peptides. Int J Cancer 1995; 60: 280-284.
52. Boman HG. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 1995; 13:61-92.
53. Srisailam S, Kumar TKS, Arunkumar AI, Leung KW, Yu C, Chen HW. Crumpled structure of the custom hydrophobic lytic peptide cecropin B3. Eur J Biochem 2001; 268: 4278-4284.
54. Yang N, Lejon T, Rekdal O. Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin derived peptide. J Peptide Sci 2003; 9: 300-311.
55. Hansel W, Leuschner C, Gawronska B, Enright F. Targeted destruction of prostate cancer cells and xenografts by lyric peptide-bLH conjugates. Reprod Biol 2001; 1:20-32.
56. Leuschner C, Enright FM, Melrose PA, Hansel W. Targeted destruction of androgen-sensitive and insensitive prostate cancer cells and xenografts through luteinizing hormone receptors. Prostate 2001; 46:116-125.
57. Gawronska B, Leuschner C, Enright FM, Hansel W. Effects of a lytic peptide conjugated to β hCG on ovarian cancer: studies in vitro and in vivo. Gyn Oncol 2002; 85: 45-52.
58. Leuschner C, Enright FM, Gawronska B, Hansel W. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 2003; 78: 17-127.
59. Bodek G, Rahman NA, Zaleska M, Sokiyamani R, Lankinen H, Hansel W, et al. A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGβ conjugate. Breast Cancer Res Treat 2003, 79: 1-10.
60. Leuschner C, Enright FM, Gawronska B, Hansel W. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors. Prostate 2003; 56: 239-249.
61. Mutwiri GK, Henk WG, Enright FM, Corbeil LB. Effect of the antimicrobial peptide, D-hecate on trichomonads. J Parasitol, 2000; 86: 1355-1359.
62. Arrowood MJ, Jaynes JJ, Healey MC. Hemolytic properties of lytic peptides active against the sporozoites of cryptosporidium parvum. J Protozool 1991; 38: 161S-163S.
63. Selsted ME, Novotny MJ, Morris ML, Tan YQ. Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. J Biol Chem 1992; 267: 4292-4295.
64. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In vitro characterization of the anticancer activity of membrane active cationic peptides. I. Peptide-mediated cytotoxicity and peptide -enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anti-cancer Drug Des 2000; 15: 151-160.
65. Leippe M, Anra J, Mueller Ebhard HJ. Cytolytic and antibacterial activity of synthetic peptides derived from amoebapore, the pore forming peptide of Entamoeba histolytica. Proc Natl Acad Sci USA 1994; 91: 2602-2606.
66. Robertson CN, Roberson KM, Pinero A, Jaynes JJ, Paulson DF. Peptidyl membrane interactive molecules are cytotoxic to prostatic cancder cells in vitio. World J Urol 1998; 18: 405-409.
67. Arlotti JA, Cimino TS, Nguen TS, Dhir R, Getzenberg RH. Efficacy of a synthetic lyric peptide in the treatment of prostate cancer. Urologic Oncol 2001; 6: 97-102.
68. Baghian A, Jaynes J, Enright FM, Kousoulas KG. An amphipathic α-helical synthetic peptide analog of melittin inhibits herpes simplex virus-1 (HSV-1)-induced cell fusion and virus spread. Peptides 1997; 18: 177-183.
69. O'Neil KT, DeGrado WFA. A thermodynamic scale for the helix-forming tendencies of the commonly occurring amino acids. Science 1990; 250: 646.
70. Javadpour MM, Barkley MD. Self-assembly of designed antimicrobial peptides in solution and micelles. Biochemistry 1997; 36: 9540-9549.
71. Moore AJ, Devine DA, Bibby MC. Preliminary experimental anticancer activity of cecropins. Peptide Research 1994; 7: 265.
72. Jing N, Urry DW. Ion Pair binding of Ca and Cl ions in micellar-packaged gramicidin A. Biochim Biophys Acta 1995; 1238: 12-21.
73. Borgnia MJ, Eytan GD, Assaraf YG. Competition of hydrophobic peptides, cytotoxic drugs, chemosensitizers on a common p-glycoprotein pharmacophore as revealed by it's ATPase activity. J Biol Chem 1996; 271: 3163-3171.
74. Warren P, Li L, Song W, Holle E, Wei Y, Wagner T, et al. In vitro targeted killing of prostate tumor cells by a synthetic amoebapore Helix 3 peptide modified with two γ-linked glutamate residues at the COOH terminus. Cancer Res 2003; 61: 6783-6787.
75. Bodek G, Vierre S, Hansel W, Huhtaniemi I, Ziecik A J, Rahman N. A. Targeted ablation of Leydig and granulosa cell tumors through their luteinizing hormone receptor (LHR) using Hecate-CGbeta conjugate in transgenic mice. Proc Soc Study of Fertil Annual Conference 2002; (Abstract)
76. Rao CV. The beginning of a new era in reproductive biology and medicine: Expression of low levels of functional luteinizing hormone/human chorionic gonadotropin receptors in nongonadal tissues. Journal of Physiology and Pharmacology 1996; 47: 41-53.
77. Leuschner C, Enright FM, Hansel W. Lytic peptide CG conjugate destroys breast cancer metastases. Proc Am Ass Cancer Res 2003; 44: 1352.
78. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Groom AC, Chambers AF. Ineffectiveness of cytotoxic chemotherapy on dormant solitary tumor cells. Proc Am Ass Cancer Res 2003; 44: 1352.
79. Galanski M, Arion VB, Jakupec MA, Keppler BK. Recent developments in the field of tumor-inhibiting metal complexes. Curr Pharm Design 2003; 9(25): 2079-89.
80. Gennaro R, Zanetti M, Benincasa M, Podda E, Miani M. Pro-rich antimicrobial peptides from animals: structure, biological functions and mechanism of action. Curr Pharm Design 2002; 8(9): 763-78.
81. Shai Y. From innate immunity to de-novo designed antimicrobial peptides. Curr Pharm Design 2002; 8(9): 715-25.